A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.

A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.

Item
http://www.wikidata.org/entity/Q43232822
Structural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congenersThe metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.Pathophysiological roles for purines: adenosine, caffeine and urate.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivoAntidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats.Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Moonlighting adenosine deaminase: a target protein for drug development.Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor.Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.Unsupervised quantification of whisking and head movement in freely moving rodents.
P2860

A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.

Item
http://www.wikidata.org/entity/Q43232822
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A new ethyladenine antagonist of adenosine A
@nl
A new ethyladenine antagonist ...... n as an antiparkinsonian drug.
@en
type
label
A new ethyladenine antagonist of adenosine A
@nl
A new ethyladenine antagonist ...... n as an antiparkinsonian drug.
@en
prefLabel
A new ethyladenine antagonist of adenosine A
@nl
A new ethyladenine antagonist ...... n as an antiparkinsonian drug.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
A new ethyladenine antagonist ...... n as an antiparkinsonian drug.
@en
P2093
P304
P31
P356
10.1016/J.NEUROPHARM.2009.11.012
P433
P478
P50
P577
P5875
P698